Locate Bio

Locate Bio is an innovative United Kingdom MedTech company focused on orthobiologics — biologically based products used in musculoskeletal surgery. The company describes itself as building a world-leading, diversified orthobiologics business that aims to give surgeons a choice of best-in-class products, with the stated purpose of relieving suffering and restoring quality of life. Its core technical capabilities are industry-leading drug delivery and tissue scaffold technologies, which it combines into what it calls Instructive Tissue Scaffolds™ and Programmed Drug Release. Locate Bio's development pipeline centres on rhBMP-2 (recombinant human bone morphogenetic protein-2) bone grafts. Its lead product, LDGraft™, is an rhBMP-2 bone graft in development and is currently in a clinical trial for lumbar interbody fusion procedures. LDGraft has also received an FDA Breakthrough Device designation for the Anterior Lumbar Interbody Fusion (ALIF) indication at one level from L3-S1 for patients with degenerative disc disease. A second rhBMP-2 product, OsteoMime™, remains in 'stealth mode'. The company is also developing CertOss™, a novel 100% synthetic bone graft based on calcium phosphate materials with instructive geometric clues, developed through a disciplined R&D process evaluating a variety of geometries. The company is headquartered in Beeston, United Kingdom, and operates with a presence in the United States through Locate Bio Inc. Its leadership team includes Chief Executive Officer John von Benecke, Chief Medical Officer Hyun W. Bae, MD, Non-Executive Chair Keith Valentine, and Tyler Lipschultz as President of Locate Bio Inc. The wider team covers quality assurance and regulatory affairs, clinical, finance, scientific programme management, human resources, and lead scientific roles, supported by non-executive directors including Ian Wilding and Alex Gwyther. Locate Bio positions itself at the intersection of drug delivery and tissue engineering, aiming to develop next-generation products capable of dominating each of their market segments. Its products are investigational and not approved for sale. The company's focus on rhBMP-2 bone grafts 'inspired by nature' for a more biomimetic presentation of the molecule reflects a strategy of differentiating through biomimetic design and synthetic materials rather than conventional graft substitutes.

Locate Bio is a United Kingdom-based MedTech company focused on orthobiologics, headquartered in Beeston. The company describes itself as an innovative UK MedTech company with industry-leading drug delivery and tissue scaffold capabilities, and it has built its identity around the goal of becoming a world-leading, diversified orthobiologics business. From its public materials, Locate Bio's development strategy centres on two technology pillars: Instructive Tissue Scaffolds™ and Programmed Drug Release. These are combined to create orthobiologic products that the company believes have massive disruptive potential, with the aim of offering better choices for surgeons and better outcomes for patients. Its stated purpose is developing next-generation solutions that address unmet musculoskeletal needs, and its culture is described as unleashing and realising potential within a fearless organisation. The company's lead programme is LDGraft™, an rhBMP-2 bone graft in development. LDGraft is currently in a clinical trial for lumbar interbody fusion procedures and has received an FDA Breakthrough Device designation for the Anterior Lumbar Interbody Fusion (ALIF) indication at one level from L3-S1 for patients with degenerative disc disease. A second rhBMP-2 product, OsteoMime™, is described as still in 'stealth mode'. Locate Bio is also developing CertOss™, a novel 100% synthetic bone graft, through a disciplined R&D process that evaluated a variety of geometries to deliver the product. Locate Bio's approach to rhBMP-2 is described as 'inspired by nature', aiming for a more biomimetic presentation of the molecule, alongside 100% synthetic calcium phosphate materials with instructive geometric clues. This reflects a research philosophy that combines biological signalling with material geometry to guide tissue regeneration. The company operates with a leadership team that includes CEO John von Benecke, Chief Medical Officer Hyun W. Bae, MD, Non-Executive Chair Keith Valentine, and Tyler Lipschultz as President of Locate Bio Inc, indicating a transatlantic operational footprint with a US entity. The broader team includes roles spanning quality assurance and regulatory affairs, clinical operations, finance, scientific programme management, human resources, and lead scientific research, with non-executive directors Ian Wilding and Alex Gwyther providing board oversight. As of its public communications, Locate Bio's products are investigational and not approved for sale. The company continues to position itself at the intersection of drug delivery and tissue engineering, pursuing a pipeline of orthobiologic products intended to address unmet needs in musculoskeletal surgery.

• LDGraft™ enters a clinical trial for lumbar interbody fusion procedures.

• LDGraft™ receives FDA Breakthrough Device designation for the ALIF indication at one level from L3-S1 for patients with degenerative disc disease.

Building a world-leading, diversified orthobiologics company focused on providing surgeons with a choice of best-in-class products; developing next-generation products capable of dominating each of their market segments.

• LDGraft™

  An rhBMP-2 bone graft in development, currently in a clinical trial for lumbar interbody fusion procedures; has an FDA Breakthrough Device designation for the ALIF indication at one level from L3-S1 for patients with degenerative disc disease. For investigational use only, not approved for sale.

• OsteoMime™

  A second rhBMP-2 product in development, described as still in 'stealth mode'.

• CertOss™

  A novel, 100% synthetic bone graft being developed through a disciplined R&D process that evaluated a variety of geometries.

1. 1Locate Bio – Defining the future of Orthobiologicslocatebio.com
2. 2About – Locate Biolocatebio.com
3. 3Products – Locate Biolocatebio.com
4. 4Locate Bio (United Kingdom) – Wikidatawikidata.org
5. 5Locate Bio Acquires Complementary Late Stage Orthobiologics Assets, Accelerating Ambition of Building a World Leading, Diversified Orthobiologics Companyfinanznachrichten.de
6. 6Locate Bio acquires orthobiologics assets from RCSIsiliconrepublic.com